Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs
Investigational and unapproved. Findings below describe what trials and reports have observed. Nothing here is an endorsement, a claim of safety or effectiveness, or a clinical recommendation.

MariTide

INVESTIGATIONAL

GLP-1 receptor agonist and GIP receptor antagonist peptide-antibody conjugate

8
graded results
0
ongoing records
5
effect domains
Evidence spread
High evidence 0Moderate evidence 5Low evidence 0Very low evidence 3

MariTide is investigational in the scoped programme below. Study records do not establish approval, safety or personal suitability. Results describe observations and do not provide treatment advice.

Dated status sources

INVESTIGATIONAL Global programme; Obesity; Subcutaneous injection; as of 2026-07-13. Amgen

The grade rates how strong the evidence is, not how good or safe the drug is. A low or very-low grade means the evidence is thin, not that an effect is harmful or ruled out.

MariTide INVESTIGATIONAL
weight-loss Decrease
Moderate evidence

Once-monthly subcutaneous maridebart cafraglutide produced substantial weight reduction without an apparent plateau at 52 weeks in adults with obesity (no diabetes);...

Jastreboff AM et al. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - ... Source
Full findingOnce-monthly subcutaneous maridebart cafraglutide produced substantial weight reduction without an apparent plateau at 52 weeks in adults with obesity (no diabetes); dose-ranging.
PopulationObesity cohort, N=465 (63% female; mean age 47.9 y; mean BMI 37.9); 52 wk; phase 2 double-blind RCT; comparator placebo
Fundingindustry - Amgen
Comparatorsplacebo
MariTide INVESTIGATIONAL
weight-loss Decrease
Moderate evidence

Weight reduction in the obesity-with-type-2-diabetes cohort, lower in magnitude than the non-diabetes cohort.

Jastreboff AM et al. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - ... Source
PopulationObesity + T2D cohort, N=127 (42% female; mean age 55.1 y; mean BMI 36.5); 52 wk; phase 2 RCT; placebo comparator
Fundingindustry - Amgen
Comparatorsplacebo
MariTide INVESTIGATIONAL
weight-loss Decrease
Very low evidence

Maridebart cafraglutide (MariTide; formerly AMG 133) is a peptide-antibody conjugate that ANTAGONISES the GIP receptor while AGONISING the GLP-1 receptor; half-life...

Amgen, Phase 2 MariTide presented at ADA 85th Scientific Sessions 2025; earlier topline N... Source
Full findingMaridebart cafraglutide (MariTide; formerly AMG 133) is a peptide-antibody conjugate that ANTAGONISES the GIP receptor while AGONISING the GLP-1 receptor; half-life ~21 days. In phase 2 (NEJM 2025), mean weight change at 52 weeks was -12.3% to -16.2% in obesity without T2D (vs -2.5% placebo) and -8.4% to -12.3% in T2D (vs -1.7% placebo) on the treatment-policy (ITT) estimand, with weight loss not plateaued by 52 weeks. HbA1c fell 1.2 to 1.6 percentage points in the T2D cohort.
PopulationPhase 2 (NCT05669599): N=592. Cohort A obesity no T2D (n=465); Cohort B obesity with T2D (n=127). Monthly fixed doses 140/280/420 mg + 8-week 420 mg arm vs placebo; 52 wk
Fundingindustry (company press release on own pipeline)
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
MariTide INVESTIGATIONAL
pharmacology Not directional
Moderate evidence

Long-acting peptide-antibody (anti-GIPR monoclonal antibody) conjugate combining GLP-1R agonism with GIPR antagonism; supports once-monthly (q4w) and tested q8w dosing.

Jastreboff AM et al. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - ... Source
PopulationMechanistic/PK description; phase 2
Fundingindustry - Amgen
MariTide INVESTIGATIONAL
pharmacology Mixed
Very low evidence

Rodent mechanistic comparison: GIPR agonism vs antagonism produce distinct metabolic profiles despite both lowering weight in obese mice.

Davies I et al. A metabolic comparison of GIPR agonism versus GIPR antagonism in male mic... Source
PopulationLean and high-fat-diet obese male mice; preclinical
Fundingacademic/independent analysis (manufacturer not study sponsor; per-study COI not individually audited)
ComparatorsGIPR agonist GIP108; GIPR antagonist NN-GIPR-Ant; pair-fed controls
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
MariTide INVESTIGATIONAL
body-composition Decrease
Very low evidence

Most weight lost attributed to fat mass; body composition improved (company-reported at ADA 2025).

Amgen press release: Results from Amgen's phase 2 obesity study of monthly MariTide prese... Source
PopulationPhase 2 obesity cohorts; 52 wk; placebo comparator
Fundingindustry - Amgen
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
MariTide INVESTIGATIONAL
glycaemic Decrease
Moderate evidence

HbA1c reduction in the obesity + T2D cohort.

Jastreboff AM et al. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - ... Source
PopulationObesity + T2D cohort, N=127; 52 wk; phase 2 RCT; placebo comparator
Fundingindustry - Amgen
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
MariTide INVESTIGATIONAL
Stomach and gut Increase
Moderate evidence

Gastrointestinal adverse events common but mitigated by lower starting dose and dose escalation.

Jastreboff AM et al. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - ... Source
PopulationFull phase 2 population N=592; 52 wk; placebo comparator
Fundingindustry - Amgen
Comparatorsplacebo